PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma

New England Journal of Medicine

Volumn 374, Issue 26, 2016, Pages 2542-2552

  Nghiem, Paul T ^a,b   Bhatia, Shailender ^a,b   Lipson, Evan J ^e   Kudchadkar, Ragini R ^g   Miller, Natalie J ^a   Annamalai, Lakshmanan ^h   Berry, Sneha ^e   Chartash, Elliot K ^h   Daud, Adil ⁱ   Fling, Steven P ^b,c   Friedlander, Philip A ^k   Kluger, Harriet M ^l   Kohrt, Holbrook E ^j   Lundgren, Lisa ^b,c   Margolin, Kim ^j   Mitchell, Alan ^d   Olencki, Thomas ^m   Pardoll, Drew M ^e   Reddy, Sunil A ^j   Shantha, Erica M ^a   Sharfman, William H ^e   Sharon, Elad ^f   Shemanski, Lynn R ^d   Shinohara, Michi M ^a   Sunshine, Joel C ^e   Taube, Janis M ^e   Thompson, John A ^a,b   Townson, Steven M ^h   Yearley, Jennifer H ^h   Topalian, Suzanne L ^e   Cheever, Martin A ^a,b,c   more..

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b USA   (United States)

^c Cancer Immunotherapy Trials Network   (United States)

^d Cancer Research and Biostatistics   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g EMORY UNIVERSITY   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j STANFORD UNIVERSITY   (United States)

^k MOUNT SINAI MEDICAL CENTER   (United States)

^l YALE UNIVERSITY   (United States)

^m OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; MALE; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MULTICENTER STUDY; MYOCARDITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEROLOGY; SYSTEMIC THERAPY; TREATMENT RESPONSE; VIRUS LOAD; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, MERKEL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SKIN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, MERKEL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; RECURRENCE; SKIN NEOPLASMS;

EID: 84976511909     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1603702     Document Type: Article

References (40)

1. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
2. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61.
3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54.
4. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8.
5. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20.
6. Iyer J, Blom A, Doumani R, et al. Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients. J Clin Oncol 2014; 32: Suppl:52. abstract.
7. Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000; 18: 2493-9.
8. Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 2013; 133:642-6.
9. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319:1096-100.
10. Iyer JG, Afanasiev OK, McClurkan C, et al. Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 2011; 17: 6671-80.
11. Afanasiev OK, Yelistratova L, Miller N, et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013; 19: 5351-60.
12. Paulson KG, Carter JJ, Johnson LG, et al. Antibodies to Merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in Merkel cell carcinoma patients. Cancer Res 2010; 70:8388-97.
13. Wong SQ, Waldeck K, Vergara IA, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res 2015; 75: 5228-34.
14. Harms PW, Vats P, Verhaegen ME, et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res 2015; 75:3720-7.
15. Goh G, Walradt T, Markarov V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncot a rget 2016; 7:3403-15.
16. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37.
17. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1:54-63.
18. Dowlatshahi M, Huang V, Gehad AE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol 2013; 133:1879-89.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
21. National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events v4.0. May 28, 2009 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf).
22. Shuda M, Arora R, Kwun HJ, et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer 2009; 125: 1243-9.
23. Doumani R, Moshiri A, Yelistratova L, et al. Detection of the Merkel cell polyomavirus in human Merkel cell carcinomas and the clinical implications of tumor viral status. J Invest Dermatol 2015; 135: Suppl S44. abstract.
24. Lyngaa R, Pedersen NW, Schrama D, et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res 2014; 20:1768-78.
25. Paulson KG, Iyer JG, Tegeder AR, et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29:1539-46.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
27. Berger RL More powerful tests from confidence interval p values. Am Stat 1996; 50: 314-8.
28. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambro lizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44.
29. Behr DS, Peitsch WK, Hametner C, et al. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. Int J Clin Exp Pathol 2014; 7: 7610-21.
30. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
31. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015; 372:2018-28.
32. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35.
33. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373:1803-13.
34. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-9.
35. Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck: preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 2015; 33: Suppl: LBA6008. abstract.
36. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62.
37. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71.
38. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV associated head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1733-41.
39. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999; 85:2589-95.
40. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-8.